Εμφάνιση μηνυμάτων

Αυτό το τμήμα σας επιτρέπει να δείτε όλα τα μηνύματα που στάλθηκαν από αυτόν τον χρήστη. Σημειώστε ότι μπορείτε να δείτε μόνο μηνύματα που στάλθηκαν σε περιοχές που αυτήν την στιγμή έχετε πρόσβαση.

Θέματα - Rose

Σελίδες: [1] 2 3 ... 93
Caesar's Messiah (Ο Μεσσίας του Καίσαρα) - ελληνικοί υπότιτλοι

Cannabinoid System in Neuroprotection, Raphael Mechoulam,PhD

Professor at Hebrew University in Jerusalem, Dr. Mechoulam describes the role of Cannabinoids as anti-inflammatory for arthritis, as neuroprotectant for brain injury and as a possible treatment for PTSD. Dr. Mechoulam first isolated THC in 1964.

Δηλητηριάζουν τα παιδιά μας, με τοξικά φαρμάκια, και δημιουργούν περισσότερες ασθένειες... αδυναμίες, υπογεννητικότητα, και γενοκτονίες εθνών εν τέλη... μια και προκαλούν τόσους θανάτους. Αυτοί οι δολοφόνοι και όλοι οι συνεργάτες τους θα πρέπει πραγματικά να καταδικαστούν σε θάνατο, μια και έχουν προκαλέσει εκατομμύρια θανάτους και έχουν καταστρέψει εκατομμύρια παιδιά... Πρέπει όλοι μας να ενημερωθούμε και να προστατέψουμε την ζωή των παιδιών μας, της δικής μας, των συγγενών μας, και όλων των συνανθρώπων μας, απλώνοντας την Αλήθεια...

Silent Epidemic; The Untold Story of Vaccines Movie dire


Εγκλημα στο χώρο της Υγείας / Exposing the Truth about Vaccines
« στις: Μάρτιος 14, 2017, 05:00:45 »
If you don't at least doubt the safety or effectiveness of vaccines you definitely will after this video. Dr. Bergman uncovers the truth about several vaccines and explains why they are not safe or effective.

Exposing the Truth about Vaccines


No Vaccines Necessary, that's the truth.

HPV Vaccine Used as Population Control?



60 Lab Studies Now Confirm Cancer Link to a Vaccine You Probably Had as a Child

Dr. Maurice Hilleman made astounding revelations in an interview that was cut from The Health Century -- the admission that Merck drug company vaccines had been injecting dangerous viruses into people worldwide.

Bear in mind that Dr. Hilleman was the developer of Merck's vaccine program. He developed over three dozen vaccines, more than any other scientist in history. He was a member of the U.S. National Academy of Science, the Institute of Medicine, the American Academy of Arts and Sciences, and the American Philosophical Society. He received a special lifetime achievement award from the World Health Organization. Hilleman was one of the early vaccine pioneers to warn about the possibility that simian viruses might contaminate vaccines.

ΥΓ. Τι σύνδεση λοιπόν έχουν οι Ηoax, η Φαρμακοβιομηχανία Merck, τα εμβόλια και ο καρκίνος? Παραπάνω αποκαλύπτεται η τραγωδία, της Δολοφονίας του Ελληνικού Λαού, και τα πρακτοράκια προδότες, που εργάζονται για την τσέπη τους, και κυνηγούν όσους φανερώνουν την Αλήθεια, αδιαφορώντας πόσα παιδιά και ενήλικες χάνουν άδικα την ζωή τους από το Καρτέλ των Φαρμακοβιομηχανιών... Και για να τα λέμε πλέον στα ίσια... Εφτιαξαν εμβόλια που δημιουργούν καρκίνο για να πουλήσουν χημειοθεραπεία... Αν δεν πρέπει να μπουκάρουμε μέσα στο χώρο Υγείας και να τα κάνουμε λίμπα απαγορεύοντας όλα τα εμβόλια και τις χημειοθεραπείες, τότε είμαστε υπεύθυνοι της θυματοποιημένης και κακόμοιρης ζωής μας...

Vaccine pioneer admits adding cancer-causing virus to Vaccine


Ο λόγος του Dr Rath στις 30 Απριλίου 2012 στην Αθήνα. Ποιος ο ρόλος των καρτέλ των φαρμάκων και του πετρελαίου. Η προσπάθεια τους να κατακτήσουν την Ευρώπη και τον κόσμο στο 1ο και 2ο παγκόσμιο πόλεμο.Οι αποδείξεις. Οι ναζιστικές καταβολές της Ευρωπαϊκής Ένωσης των Βρυξελλών και η τρίτη προσπάθεια του καρτέλ να κατακτήσει την Ευρώπη και τον κόσμο.Ο έλεγχος της υγείας και της ενέργειας. Η νέα μετάβαση και πως μπορούν οι λαοί να ανατρέψουν τα σχέδια τους. Η Ελλάδα .

DR. RATH OMILIA ATHINA 30 APRILIOY 2012( me ellinikous ypotitlous) (with Greek subtitles)

Study Shows Chemotherapy Killing Many Cancer Patients Within 30 Days Of Starting Treatment

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (≥10% viable tumour) improved event-free survival in patients with high-grade osteosarcoma.

EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisation. Patients were randomly assigned (1:1) to receive either postoperative cisplatin, doxorubicin, and methotrexate (MAP) or MAP plus ifosfamide and etoposide (MAPIE) using concealed permuted blocks with three stratification factors: trial group; location of tumour (proximal femur or proximal humerus vs other limb vs axial skeleton); and presence of metastases (no vs yes or possible). The MAP regimen consisted of cisplatin 120 mg/m2, doxorubicin 37·5 mg/m2 per day on days 1 and 2 (on weeks 1 and 6) followed 3 weeks later by high-dose methotrexate 12 g/m2 over 4 h. The MAPIE regimen consisted of MAP as a base regimen, with the addition of high-dose ifosfamide (14 g/m2) at 2·8 g/m2 per day with equidose mesna uroprotection, followed by etoposide 100 mg/m2 per day over 1 h on days 1–5. The primary outcome measure was event-free survival measured in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT00134030.

Between April 14, 2005, and June 30, 2011, 2260 patients were registered from 325 sites in 17 countries. 618 patients with poor response were randomly assigned; 310 to receive MAP and 308 to receive MAPIE. Median follow-up was 62·1 months (IQR 46·6–76·6); 62·3 months (IQR 46·9–77·1) for the MAP group and 61·1 months (IQR 46·5–75·3) for the MAPIE group. 307 event-free survival events were reported (153 in the MAP group vs 154 in the MAPIE group). 193 deaths were reported (101 in the MAP group vs 92 in the MAPIE group). Event-free survival did not differ between treatment groups (hazard ratio

0·98 [95% CI 0·78–1·23]); hazards were non-proportional (p=0·0003). The most common grade 3–4 adverse events were neutropenia (268 [89%] patients in MAP vs 268 [90%] in MAPIE), thrombocytopenia (231 [78% in MAP vs 248 [83%] in MAPIE), and febrile neutropenia without documented infection (149 [50%] in MAP vs 217 [73%] in MAPIE). MAPIE was associated with more frequent grade 4 non-haematological toxicity than MAP (35 [12%] of 301 in the MAP group vs 71 [24%] of 298 in the MAPIE group). Two patients died during postoperative therapy, one from infection (although their absolute neutrophil count was normal), which was definitely related to their MAP treatment (specifically doxorubicin and cisplatin), and one from left ventricular systolic dysfunction, which was probably related to MAPIE treatment (specifically doxorubicin). One suspected unexpected serious adverse reaction was reported in the MAP group: bone marrow infarction due to methotrexate.

EURAMOS-1 results do not support the addition of ifosfamide and etoposide to postoperative chemotherapy in patients with poorly responding osteosarcoma because its administration was associated with increased toxicity without improving event-free survival. The results define standard of care for this population. New strategies are required to improve outcomes in this setting.

UK Medical Research Council, National Cancer Institute, European Science Foundation, St Anna Kinderkrebsforschung, Fonds National de la Recherche Scientifique, Fonds voor Wetenschappelijk Onderzoek-Vlaanderen, Parents Organization, Danish Medical Research Council, Academy of Finland, Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, Federal Ministry of Education and Research, Semmelweis Foundation, ZonMw (Council for Medical Research), Research Council of Norway, Scandinavian Sarcoma Group, Swiss Paediatric Oncology Group, Cancer Research UK, National Institute for Health Research, University College London Hospitals, and Biomedical Research Centre.


Treatment strategies for high-grade osteosarcoma with multidrug chemotherapy and resection result in 3-year event-free survival of 60–70%.1, 2, 3, 4 The most common factors predicting survival are presence of metastases,1 histological response to preoperative chemotherapy,1, 5, 6, 7, 8 and complete surgical resection.1 Three of the active drugs in osteosarcoma3 include cisplatin,9, 10, 11 doxorubicin,12, 13 and high-dose methotrexate;14, 15 this combination (MAP), given preoperatively and postoperatively, is widely used for the treatment of osteosarcoma. Ifosfamide with16, 17 or without etoposide17 also has activity in this setting and when incorporated into the treatment of patients with metastatic disease seems to improve event-free survival.18 Though uncontrolled studies suggested that changing therapy on the basis of histological response improves outcomes,3, 5, 19 the efficacy of this strategy had not been tested in a randomised trial.

We report the primary results for patients who had a poor response and were randomised to the EURAMOS-1 trial, a collaboration between the Children's Oncology Group (COG), the Cooperative Osteosarcoma Study Group (COSS), the European Osteosarcoma Intergroup (EOI), and the Scandinavian Sarcoma Group (SSG). We did this trial to assess whether the addition of ifosfamide and etoposide to standard postoperative MAP would improve event-free survival in patients whose primary tumour showed a poor response to preoperative MAP.

Peter Gøtzsche - Overdiagnosed & Overmedicated

Prof Peter Gøtzsche: Why Few Patients Benefit and Many are Harmed

Peter Gøtzsche - Prescription drugs are the third leading cause of death

Γιατί λέμε ΟΧΙ στις Χημειοθεραπείες! Μουρούτης Κωνσταντίνος, Φυσίατρος Νευροβιοεπιστήμονας Μέρος 1/2""

Οικολογική Θεραπεία του Καρκίνου. Μουρούτης Κωνσταντίνος, Φυσίατρος Νευροβιοεπιστήμονας Μέρος 2/2""

Ο Dr Peter Gøtzsche εκθέτει τη φαρμακευτική βιομηχανία ως οργανωμένο έγκλημα


Σελίδες: [1] 2 3 ... 93